Jefferies Group Comments on CME Group’s FY2018 Earnings (NASDAQ:CME)

CME Group (NASDAQ:CME) – Analysts at Jefferies Group upped their FY2018 earnings estimates for shares of CME Group in a note issued to investors on Tuesday, April 3rd, Zacks Investment Research reports. Jefferies Group analyst D. Fannon now expects that the financial services provider will earn …

CME Group logo

CME Group (NASDAQ:CME) – Analysts at Jefferies Group upped their FY2018 earnings estimates for shares of CME Group in a note issued to investors on Tuesday, April 3rd, Zacks Investment Research reports. Jefferies Group analyst D. Fannon now expects that the financial services provider will earn $7.03 per share for the year, up from their previous estimate of $6.57. Jefferies Group also issued estimates for CME Group’s FY2019 earnings at $7.06 EPS.

How to Become a New Pot Stock Millionaire

CME Group (NASDAQ:CME) last announced its earnings results on Thursday, February 1st. The financial services provider reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.02. CME Group had a return on equity of 7.68% and a net margin of 111.49%. The firm had revenue of $900.00 million for the quarter, compared to the consensus estimate of $886.85 million. During the same period in the previous year, the business earned $1.14 EPS. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis.

CME has been the topic of several other reports. Sanford C. Bernstein began coverage on CME Group in a research note on Monday, April 9th. They set an “outperform” rating and a $190.00 target price on the stock. Zacks Investment Research downgraded CME Group from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Berenberg Bank began coverage on CME Group in a research note on Thursday, January 25th. They set a “hold” rating and a $170.00 target price on the stock. ValuEngine upgraded CME Group from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Goldman Sachs raised CME Group from a “neutral” rating to a “buy” rating and set a $180.00 price target for the company in a research report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. CME Group presently has an average rating of “Buy” and an average price target of $165.57.

Shares of CME stock opened at $164.47 on Thursday. CME Group has a 1-year low of $114.82 and a 1-year high of $171.71. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.10. The firm has a market cap of $56,081.83, a P/E ratio of 34.48, a price-to-earnings-growth ratio of 2.29 and a beta of 0.56.

Hedge funds have recently modified their holdings of the company. ARK Investment Management LLC acquired a new position in shares of CME Group in the 4th quarter valued at about $120,000. Valeo Financial Advisors LLC acquired a new position in CME Group in the 3rd quarter worth about $124,000. AlphaOne Investment Services LLC acquired a new position in CME Group in the 4th quarter worth about $146,000. Mosaic Family Wealth LLC acquired a new position in CME Group in the 4th quarter worth about $146,000. Finally, Truewealth LLC acquired a new position in CME Group in the 4th quarter worth about $157,000. 83.41% of the stock is owned by institutional investors and hedge funds.

In other news, insider Hilda Harris Piell sold 3,299 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $163.52, for a total value of $539,452.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Derek Sammann sold 2,400 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $161.66, for a total value of $387,984.00. Following the completion of the transaction, the insider now directly owns 40,153 shares of the company’s stock, valued at approximately $6,491,133.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,699 shares of company stock valued at $5,532,362. 0.57% of the stock is currently owned by insiders.

The company also recently declared a quarterly dividend, which was paid on Monday, March 26th. Shareholders of record on Friday, March 9th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Thursday, March 8th. This represents a $2.80 dividend on an annualized basis and a yield of 1.70%. This is a boost from CME Group’s previous quarterly dividend of $0.66. CME Group’s payout ratio is currently 58.70%.

TRADEMARK VIOLATION NOTICE: “Jefferies Group Comments on CME Group’s FY2018 Earnings (NASDAQ:CME)” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/20/fy2018-earnings-forecast-for-cme-group-inc-cme-issued-by-jefferies-group.html.

About CME Group

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Get a free copy of the Zacks research report on CME Group (CME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CME Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CME Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Alliancebernstein LP Sells 292938 Shares of Altria Group Inc (MO)

Quantum Capital Management LLC NJ acquired a new stake in shares of Altria Group in the third quarter valued at $114,000. Northwest Investment Counselors LLC raised its stake in shares of Altria Group by 557.0% in the third quarter. Northwest Investment Counselors LLC now owns 1,820 shares of …

Altria Group logoAlliancebernstein L.P. trimmed its stake in Altria Group Inc (NYSE:MO) by 2.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,522,139 shares of the company’s stock after selling 292,938 shares during the period. Alliancebernstein L.P. owned 0.55% of Altria Group worth $751,386,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in MO. NewSquare Capital LLC grew its position in Altria Group by 4,734.7% in the third quarter. NewSquare Capital LLC now owns 108,780 shares of the company’s stock worth $109,000 after acquiring an additional 106,530 shares during the period. Balentine LLC raised its stake in shares of Altria Group by 32.4% in the second quarter. Balentine LLC now owns 1,460 shares of the company’s stock valued at $109,000 after acquiring an additional 357 shares in the last quarter. Quantum Capital Management LLC NJ acquired a new stake in shares of Altria Group in the third quarter valued at $114,000. Northwest Investment Counselors LLC raised its stake in shares of Altria Group by 557.0% in the third quarter. Northwest Investment Counselors LLC now owns 1,820 shares of the company’s stock valued at $115,000 after acquiring an additional 1,543 shares in the last quarter. Finally, Oak Point Wealth Management acquired a new stake in Altria Group in the fourth quarter valued at $120,000. Hedge funds and other institutional investors own 62.54% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, CEO Brian W. Quigley sold 3,464 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $62.40, for a total value of $216,153.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP W Hildebrandt Surgner, Jr. sold 3,200 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $62.34, for a total transaction of $199,488.00. The disclosure for this sale can be found here. Insiders sold 28,117 shares of company stock valued at $1,821,707 over the last quarter. Insiders own 0.11% of the company’s stock.

MO opened at $57.78 on Friday. Altria Group Inc has a fifty-two week low of $56.08 and a fifty-two week high of $77.79. The stock has a market cap of $121,590.73, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 1.86 and a beta of 0.62. The company has a current ratio of 0.64, a quick ratio of 0.31 and a debt-to-equity ratio of 0.85.

Altria Group (NYSE:MO) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.80 by $0.11. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.80 billion. Altria Group had a net margin of 39.97% and a return on equity of 50.01%. Altria Group’s revenue was down .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.68 earnings per share. sell-side analysts predict that Altria Group Inc will post 4.01 earnings per share for the current fiscal year.

Altria Group announced that its Board of Directors has approved a stock buyback plan on Thursday, February 1st that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 10th. Stockholders of record on Thursday, March 15th were issued a $0.70 dividend. The ex-dividend date was Wednesday, March 14th. This is a boost from Altria Group’s previous quarterly dividend of $0.66. This represents a $2.80 annualized dividend and a dividend yield of 4.85%. Altria Group’s dividend payout ratio (DPR) is 82.84%.

A number of equities analysts recently issued reports on MO shares. Zacks Investment Research raised Altria Group from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a report on Monday, April 9th. Citigroup lowered Altria Group from a “buy” rating to a “neutral” rating and set a $75.00 price objective on the stock. in a report on Wednesday. Morgan Stanley decreased their price target on Altria Group from $74.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Vetr upgraded Altria Group from a “buy” rating to a “strong-buy” rating and set a $76.87 price objective for the company in a research report on Monday, February 12th. Finally, Wells Fargo boosted their price target on Altria Group from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $74.21.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://weekherald.com/2018/04/20/altria-group-inc-mo-holdings-reduced-by-alliancebernstein-l-p.html.

About Altria Group

Altria Group, Inc is a holding company. The Company’s segments include smokeable products, smokeless products and wine. The Company’s subsidiaries include Philip Morris USA Inc (PM USA), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co (Middleton), which is engaged in the manufacture and sale of machine-made cigars and pipe tobacco, and UST LLC (UST), which, through its subsidiaries, including U.S.

Institutional Ownership by Quarter for Altria Group (NYSE:MO)

Receive News & Ratings for Altria Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Altria Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Analysts See $0.74 EPS for Omega Healthcare Investors, Inc. (OHI)

Quantum Capital Management decreased its stake in Ryder Sys Inc (R) by 6.54% based on its latest 2017Q4 regulatory filing with the SEC. … Zacks Investment Research downgraded shares of Omega Healthcare Investors from a “hold” rating to a “sell” rating in a research note on Tuesday, February …

Shares are trading price at $162.12 with move of 1.19%. Barnett & Company Inc. now owns 5,200 shares of the real estate investment trust’s stock valued at $166,000 after buying an additional 4,950 shares during the last quarter. Daiwa Securities Group Inc. increased its position in Omega Healthcare Investors by 14,906.5% during the fourth quarter. The stock price dipped -0.04% in three months and plunged -16.87% for the last six months trading period. Wells Fargo stated diluted earnings per share of 1.12 dollars, and revenue of 21.9 billion dollars. After having $0.79 EPS previously, Omega Healthcare Investors, Inc.’s analysts see -6.33 % EPS growth. (NYSE:OHI) has declined 18.67% since April 18, 2017 and is downtrending. OHI underperformed by 30.22% the S&P500.

Quantum Capital Management decreased its stake in Ryder Sys Inc (R) by 6.54% based on its latest 2017Q4 regulatory filing with the SEC.

Market Capitalization/Outstanding Shares/Intraday Volume: The company’s Market capitalization is $5.20B with the total Outstanding Shares of 198.98M. A year ago the company’s sales were $231740 while its sales growth yearly estimates for the current quarter are -7.4%. The stock decreased 0.19% or $0.05 during the last trading session, reaching $25.78. (OHI) exchanged hands at an unexpectedly low level of 2.06 million shares over the course of the day. Wells Fargo & Company (NYSE:WFC) has declined 7.75% since April 19, 2017 and is downtrending. It has underperformed by 61.98% the S&P500.

A number of other analysts have also recently issued reports on OHI. OHI’s profit will be $151.36M for 9.04 P/E if the $0.73 EPS becomes a reality.

Moving average of Omega Healthcare Investors, Inc.

Productivity proportions: Investigating the productivity proportions of Omega Healthcare Shareholders, Inc., (NYSE: OHI) stock, the speculator will discover its ROE, ROA, ROI remaining at 2.7%, 1.1% and 3.2%, individually. Therefore 34% are positive. The rating was maintained by Bank of America on Monday, February 5 with “Buy”. The firm has “Neutral” rating by BTIG Research given on Thursday, August 25. JMP Securities downgraded the stock to “Mkt Perform” rating in Thursday, August 18 report. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, December 20. As per Wednesday, February 14, the company rating was maintained by SunTrust.

Omega Healthcare Investors stock opened at $26.11 on Tuesday. Omega Healthcare Investors’s payout ratio is now 131.22%. Jefferies Group now has a “Underperform” rating on the stock. (NYSE:OHI) for 187,304 shares. Moreover, Reaves W H & Co Inc has 3.64% invested in the company for 1.08 million shares. It’s up 0.08, from 1.19 in 2017Q3.

Price earnings ratio (P/E) ratio of Omega Healthcare Investors, Inc. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. 141.70 million shares or 6.90% more from 132.55 million shares in 2017Q3 were reported. State Common Retirement Fund owns 233,767 shares or 0.02% of their U.S. portfolio. Us Natl Bank De stated it has 0% of its portfolio in Omega Healthcare Investors, Inc. (NYSE:OHI). Florida-based Raymond James Associates has invested 0.03% in Omega Healthcare Investors, Inc. Omega Healthcare Investors (NYSE:OHI)’s price sits -2.82% off from its SMA 50 of $26.68 and -11.67% away from the SMA 200 which is at $27.77. The 14-day RSI for Omega Healthcare Investors, Inc. Shelton Cap Mngmt, a California-based fund reported 15,760 shares. Mercer Capital Advisers holds 0.01% or 300 shares. Cohen & Steers holds 0.45% or 5.94M shares in its portfolio. (NYSE:OHI) for 71,151 shares. Weaver C Barksdale & Associates Inc who had been investing in Omega Healthcare Invs Inc for a number of months, seems to be bullish on the $5.36 billion market cap company. (OHI) stock price moved -0.59% away from 20-Days Simple Moving Average, -0.72% from 50-Days Simple Moving Average and separated -9.49% from 200 Days Simple Moving Average. Zacks Investment Research downgraded shares of Omega Healthcare Investors from a “hold” rating to a “sell” rating in a research note on Tuesday, February 20th. ValuEngine cut Omega Healthcare Investors from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Bluefin Trading Llc bought 454,000 shares as the company’s stock declined 16.98% with the market. On Tuesday, November 3 the stock rating was maintained by Stifel Nicolaus with “Buy”. (NYSE:OHI) with “Buy” rating. RBC Capital Markets has “Outperform” rating and $124 target. The firm has “Hold” rating by Robert W. Baird given on Tuesday, October 31. The firm has “Hold” rating by SunTrust given on Monday, January 22. Rare Infrastructure Ltd owns 463,636 shares or 3.93% of their United States portfolio.

Investors sentiment decreased to 1.02 in 2017 Q4. Its up 0.04, from 0.83 in 2017Q3. It increased, as 38 investors sold STI shares while 239 reduced holdings. 143 funds opened positions while 654 raised stakes. After $0.86 actual earnings per share reported by Verizon Communications Inc. for the previous quarter, Wall Street now forecasts 30.23% EPS growth. A company with a high P/E ratio usually indicated positive future performance and investors are willing to pay more for this company’s shares. Hl Financial Ltd Limited Liability Company reported 18,847 shares. Howland Management Limited Liability Corporation invested 1.77% in Ecolab Inc. Proshare Ltd has 69,377 shares for 0.01% of their portfolio. Credit Suisse Ag invested in 467,770 shares. Hodges Cap Inc accumulated 56,953 shares. Arcadia Invest Mi has 2.07% invested in Ecolab Inc. Parametric Port Assoc Limited Liability has invested 0% in Diebold Nixdorf, Incorporated (NYSE:DBD). (NYSE:ECL). 13,881 are owned by Pub Sector Pension Invest Board. Sandy Spring Bancshares holds 0.05% or 4,096 shares. If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. Chelsea Counsel holds 1,500 shares. It also reduced Visa Inc (Put) (NYSE:V) stake by 35,000 shares and now owns 61,000 shares. Putnam Invs Llc, Massachusetts-based fund reported 29,818 shares.

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Juniper Networks, Inc. (JNPR) Shares Sold by Cornerstone Capital Management Holdings LLC.

Cornerstone Capital Management Holdings LLC. trimmed its stake in Juniper Networks, Inc. (NYSE:JNPR) by 82.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,000 shares of the network equipment provider’s …

Juniper Networks logoCornerstone Capital Management Holdings LLC. trimmed its stake in Juniper Networks, Inc. (NYSE:JNPR) by 82.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,000 shares of the network equipment provider’s stock after selling 384,329 shares during the period. Cornerstone Capital Management Holdings LLC.’s holdings in Juniper Networks were worth $2,308,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Juniper Networks in the 3rd quarter valued at $111,000. Cerebellum GP LLC acquired a new stake in Juniper Networks during the 4th quarter worth $128,000. Exane Derivatives boosted its stake in Juniper Networks by 278.1% during the 4th quarter. Exane Derivatives now owns 5,633 shares of the network equipment provider’s stock worth $161,000 after purchasing an additional 4,143 shares during the period. Balter Liquid Alternatives LLC acquired a new stake in Juniper Networks during the 4th quarter worth $163,000. Finally, Wetherby Asset Management Inc. acquired a new stake in Juniper Networks during the 4th quarter worth $209,000. 95.49% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of NYSE JNPR traded up $0.06 during midday trading on Thursday, hitting $24.44. The company had a trading volume of 4,309,116 shares, compared to its average volume of 4,443,887. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.46. Juniper Networks, Inc. has a twelve month low of $23.61 and a twelve month high of $30.96. The stock has a market capitalization of $8,734.86, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 2.96 and a beta of 0.96.

Juniper Networks (NYSE:JNPR) last announced its quarterly earnings data on Tuesday, January 30th. The network equipment provider reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.01. Juniper Networks had a net margin of 6.26% and a return on equity of 13.34%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.23 billion. During the same quarter last year, the business earned $0.66 earnings per share. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year. equities research analysts expect that Juniper Networks, Inc. will post 1.34 EPS for the current fiscal year.

Juniper Networks declared that its board has authorized a stock buyback plan on Tuesday, January 30th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the network equipment provider to repurchase shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 22nd. Investors of record on Thursday, March 1st were paid a $0.18 dividend. This is a boost from Juniper Networks’s previous quarterly dividend of $0.10. The ex-dividend date of this dividend was Wednesday, February 28th. This represents a $0.72 annualized dividend and a dividend yield of 2.95%. Juniper Networks’s dividend payout ratio (DPR) is 41.62%.

In other Juniper Networks news, EVP Vincent Molinaro sold 7,647 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $26.21, for a total transaction of $200,427.87. Following the completion of the transaction, the executive vice president now directly owns 17,989 shares in the company, valued at approximately $471,491.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Rami Rahim sold 5,300 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $26.24, for a total transaction of $139,072.00. The disclosure for this sale can be found here. Insiders sold 42,813 shares of company stock valued at $1,124,709 in the last quarter. Company insiders own 2.60% of the company’s stock.

A number of analysts recently weighed in on JNPR shares. Deutsche Bank reiterated a “sell” rating and set a $20.00 price target on shares of Juniper Networks in a research note on Friday, January 5th. Goldman Sachs cut shares of Juniper Networks from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $26.00 to $21.00 in a research note on Wednesday. CIBC upgraded shares of Juniper Networks from a “market perform” rating to an “outperform” rating in a research note on Monday, January 22nd. UBS upgraded shares of Juniper Networks from a “market perform” rating to an “outperform” rating in a research note on Monday, January 22nd. Finally, Oppenheimer upgraded shares of Juniper Networks from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a research note on Monday, January 22nd. Four analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $28.41.

TRADEMARK VIOLATION WARNING: This report was reported by Macon Daily and is the property of of Macon Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://macondaily.com/2018/04/19/juniper-networks-inc-jnpr-position-decreased-by-cornerstone-capital-management-holdings-llc-updated-updated-updated.html.

Juniper Networks Company Profile

Juniper Networks, Inc designs, develops and sells products and services for high-performance networks to enable customers to build networks for their businesses. The Company sells its products in over 100 countries in three geographic regions: Americas; Europe, the Middle East and Africa, and Asia Pacific.

Institutional Ownership by Quarter for Juniper Networks (NYSE:JNPR)

Receive News & Ratings for Juniper Networks Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Juniper Networks and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Sangamo Therapeutics Inc (NASDAQ:SGMO) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP lifted its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 1,403.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 194,719 shares of the …

Sangamo Therapeutics logoTwo Sigma Investments LP lifted its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 1,403.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 194,719 shares of the biopharmaceutical company’s stock after purchasing an additional 181,770 shares during the period. Two Sigma Investments LP owned 0.23% of Sangamo Therapeutics worth $3,193,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Sangamo Therapeutics by 81.5% during the second quarter. Dimensional Fund Advisors LP now owns 233,752 shares of the biopharmaceutical company’s stock worth $2,057,000 after purchasing an additional 104,988 shares in the last quarter. Nationwide Fund Advisors lifted its position in Sangamo Therapeutics by 13.5% in the 3rd quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 5,337 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in Sangamo Therapeutics in the 3rd quarter valued at $220,000. New York State Common Retirement Fund lifted its position in Sangamo Therapeutics by 48.6% during the 3rd quarter. New York State Common Retirement Fund now owns 113,230 shares of the biopharmaceutical company’s stock worth $1,698,000 after buying an additional 37,030 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Sangamo Therapeutics by 7.4% during the 3rd quarter. Rhumbline Advisers now owns 88,816 shares of the biopharmaceutical company’s stock worth $1,332,000 after buying an additional 6,125 shares in the last quarter. 64.69% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

NASDAQ:SGMO traded down $0.25 on Thursday, hitting $19.20. The company had a trading volume of 1,767,495 shares, compared to its average volume of 2,183,104. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.54 and a quick ratio of 5.54. Sangamo Therapeutics Inc has a 52 week low of $4.05 and a 52 week high of $27.50. The company has a market cap of $1,685.77, a price-to-earnings ratio of -27.43 and a beta of 2.80.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The firm had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $11.10 million. During the same period in the prior year, the company posted ($0.14) EPS. The company’s revenue was up 46.6% on a year-over-year basis. analysts expect that Sangamo Therapeutics Inc will post -0.15 EPS for the current year.

In other Sangamo Therapeutics news, Director Steven J. Mento sold 11,520 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $20.59, for a total value of $237,196.80. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at $102,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $25.56, for a total transaction of $127,800.00. Following the completion of the transaction, the chief financial officer now directly owns 12,250 shares in the company, valued at $313,110. The disclosure for this sale can be found here. Insiders sold 103,059 shares of company stock valued at $2,214,622 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.

SGMO has been the topic of several analyst reports. ValuEngine raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Barclays restated a “buy” rating and set a $30.00 price objective on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Jefferies Group reiterated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 17th. Finally, Piper Jaffray set a $25.00 price objective on shares of Sangamo Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $20.83.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2018/04/19/two-sigma-investments-lp-acquires-181770-shares-of-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sangamo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts